
Drug developer Tenaya Therapeutics' TNYA.O shares slide 12.5% to $1.19 in extended trading
TNYA unveils public offering of common stock and warrants; size not disclosed
Leerink Partners and Piper Sandler are joint bookrunning managers for offering
Separately, TNYA announces data from early trial for experimental gene therapy in rare heart condition
TNYA has 166.5 million outstanding shares for $233 million market cap, per LSEG data
All eight brokerages covering the stock rate it "buy" or higher; median PT $5 - data compiled by LSEG
As of last close, TNYA stock down 4.9% YTD